Building an Australian Baseline Patch Series From 5,281 Patients
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
Reader question: How did 5,281 local patch tests inform an Australian baseline series?
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 5,281 patients patch tested through Australian contact-dermatitis services. |
| Design | Retrospective surveillance analysis used to recommend allergens for the first Australian baseline series. |
| Comparator | Allergen positivity and relevance were compared to determine which allergens merited baseline inclusion; occupational and nonoccupational exposures contributed. |
| Timepoint | The indexed abstract describes accumulated clinic data but does not specify the full calendar interval. |
| Key result | The study analyzed patch-test experience in 5,281 patients to construct a locally relevant baseline series rather than importing another region's panel unchanged. |
| Funding/conflict context | The indexed abstract does not state funding or conflicts. No moisturizer was evaluated. |
What was actually measured?
The study analyzed patch-test experience in 5,281 patients to construct a locally relevant baseline series rather than importing another region's panel unchanged.
A baseline series is a diagnostic screening tool shaped by local exposure patterns; inclusion does not mean every positive reaction is clinically or occupationally relevant.
The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.
What the result does not prove
Referral data, clinic-specific testing, incomplete calendar detail in the abstract and changing exposures limit prevalence interpretation and future durability.
Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.
A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.
Exposure detail matters more than the job label
Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.
A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.
Questions worth recording
- Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
- Where did the change begin, and did it improve on days away or after a process or PPE change?
- How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
- Were labels, ingredient information and safety-data sheets reviewed with occupational health?
- Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?
Prevention comes before cosmetic care
Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.
Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.
Primary research and guidance
- Primary research record: PubMed PMID 25196101
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis
- American Academy of Dermatology: eczema skin care
Where Dr. Arsy #003 fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.
Continue the evidence series
- Objective Skin-Barrier Measures in 185 Physicians, Dentists and Controls
- Hand-to-Forearm Barrier Measures in 148 Physicians and Dentists
- Six-Month Outcomes in 1,048 Occupational-Skin Patients
- Oil-and-Cooling-Fluid Patch Tests in 175 Exposed Patients
Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.